MX2019004855A - Politerapia para tratar hipertension pulmonar. - Google Patents

Politerapia para tratar hipertension pulmonar.

Info

Publication number
MX2019004855A
MX2019004855A MX2019004855A MX2019004855A MX2019004855A MX 2019004855 A MX2019004855 A MX 2019004855A MX 2019004855 A MX2019004855 A MX 2019004855A MX 2019004855 A MX2019004855 A MX 2019004855A MX 2019004855 A MX2019004855 A MX 2019004855A
Authority
MX
Mexico
Prior art keywords
treating pulmonary
combination therapy
pulmonary hypertension
combination
inhibitor
Prior art date
Application number
MX2019004855A
Other languages
English (en)
Inventor
S Zisman Lawrence
Original Assignee
Pulmokine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmokine Inc filed Critical Pulmokine Inc
Publication of MX2019004855A publication Critical patent/MX2019004855A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente descripción muestra un método para tratar trastornos pulmonares como por ejemplo hipertensión arterial pulmonar, utilizando una combinación de un inhibidor de cinasa de receptor PDGF, un inhibidor de PDEV y un antagonista de receptor de endotelina. Los compuestos pueden inhibir el crecimiento y proliferación celulares y tienen como objetivo la patología subyacente de PAH.
MX2019004855A 2016-10-27 2017-10-27 Politerapia para tratar hipertension pulmonar. MX2019004855A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413788P 2016-10-27 2016-10-27
PCT/US2017/058768 WO2018081567A1 (en) 2016-10-27 2017-10-27 Combination therapy for treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
MX2019004855A true MX2019004855A (es) 2019-09-19

Family

ID=62020796

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004855A MX2019004855A (es) 2016-10-27 2017-10-27 Politerapia para tratar hipertension pulmonar.
MX2022000966A MX2022000966A (es) 2016-10-27 2019-04-25 Politerapia para tratar hipertension pulmonar.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000966A MX2022000966A (es) 2016-10-27 2019-04-25 Politerapia para tratar hipertension pulmonar.

Country Status (11)

Country Link
US (2) US10231966B2 (es)
EP (1) EP3532063A4 (es)
JP (2) JP2020500183A (es)
KR (2) KR102543227B1 (es)
CN (1) CN110087653A (es)
AU (1) AU2017348354B2 (es)
BR (1) BR112019008622A2 (es)
CA (1) CA3041679A1 (es)
MX (2) MX2019004855A (es)
RU (1) RU2763525C2 (es)
WO (1) WO2018081567A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023504115A (ja) * 2019-11-29 2023-02-01 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
CN117157282A (zh) 2021-05-07 2023-12-01 Gb002股份有限公司 N-{3-[(1s)-1-{[6-(3,4-二甲氧基苯基)吡嗪-2-基]氨基}乙基]苯基}-5-甲基吡啶-3-甲酰胺的结晶形式及相关产品和方法
WO2024035884A1 (en) * 2022-08-10 2024-02-15 Gb002, Inc. Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118401A (en) 1977-10-19 1978-10-03 American Hoechst Corporation Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor
JPS5488231A (en) 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5648369A (en) 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
CN1200725A (zh) 1995-08-30 1998-12-02 拜尔公司 酰基氨基水杨酰胺类化合物
JPH09268169A (ja) 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
WO2001013891A2 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6451823B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
JP2003512353A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
DE60017179T2 (de) 1999-10-19 2006-01-05 Merck & Co., Inc. Tyrosin kinaseinhibitoren
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
EP1259236A4 (en) 2000-02-25 2004-11-03 Merck & Co Inc Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
US6776309B2 (en) 2002-05-23 2004-08-17 Ben Z. Cohen Medically accurate pump system
AUPS251502A0 (en) 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
US7122550B2 (en) 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
AU2003248245A1 (en) 2002-06-26 2004-01-19 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
EP1545523A1 (en) 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
NZ537858A (en) 2002-07-15 2008-04-30 Myriad Genetics Inc Compounds, compositions, and methods employing same
JP4942297B2 (ja) 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050026879A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
DE602004025258D1 (de) 2003-08-06 2010-03-11 Vertex Pharma Aminotriazol-verbindungen als proteinkinase-hemmer
JP4724665B2 (ja) 2003-11-07 2011-07-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キノリノン化合物を合成する方法
EP1689739B1 (en) 2003-12-03 2016-03-30 YM BioSciences Australia Pty Ltd Azole-based kinase inhibitors
PL1689715T3 (pl) 2003-12-03 2011-07-29 Ym Biosciences Australia Pty Inhibitory tubuliny
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
US20080268460A1 (en) 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
KR20080066030A (ko) 2005-11-10 2008-07-15 바이엘 헬스케어 아게 폐고혈압을 치료하기 위한 디아릴 우레아
US20090197922A1 (en) 2006-01-24 2009-08-06 The University Of Chicago Compositions and methods for treating pulmonary hypertension
US8410173B2 (en) 2006-02-28 2013-04-02 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
WO2007124382A2 (en) 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
SI2848610T1 (en) 2006-11-15 2018-02-28 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity
AU2008247668B2 (en) 2007-05-04 2013-01-10 Irm Llc Pyrimidine derivatives and compositions as c-kit and PDGFR kinase inhibitors
US8338417B2 (en) 2007-05-04 2012-12-25 Irm Llc Compounds and compositions as c-kit and PDGFR kinase inhibitors
KR20120107538A (ko) 2007-08-22 2012-10-02 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
CN101784539A (zh) 2007-08-22 2010-07-21 Irm责任有限公司 作为激酶抑制剂的2-杂芳基氨基嘧啶衍生物
RU2497813C2 (ru) 2007-12-20 2013-11-10 Байер Интеллектуэль Проперти Гмбх 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
BRPI0917491A2 (pt) 2008-08-13 2015-12-01 Novartis Ag tratamento de hipertensao arterial pulmonar
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
BR112013008983A2 (pt) * 2010-10-15 2016-07-05 Gilead Sciences Inc composições e métodos de tratamento da hipertensão pulmonar
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
KR101763195B1 (ko) 2011-05-19 2017-07-31 사바라 인코포레이티드 건조 분말 반코마이신 조성물 및 관련 방법
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
KR101962495B1 (ko) 2011-09-01 2019-03-26 노파르티스 아게 C-kit 키나제 억제제로서의 화합물 및 조성물
AU2014205481A1 (en) 2013-01-10 2015-08-27 Gilead Sciences, Inc. Therapeutic indications of kinase inhibitors
JP6387488B2 (ja) 2013-01-10 2018-09-12 プルモキネ、インコーポレイテッド 非選択的キナーゼ阻害剤
NZ717528A (en) 2013-07-31 2024-07-05 Avalyn Pharma Inc Aerosol tyrosine kinase inhibitor compounds and uses thereof
EP3054937B1 (en) * 2013-10-11 2023-07-26 Pulmokine, Inc. Spray dry formulations
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors

Also Published As

Publication number Publication date
AU2017348354B2 (en) 2023-06-15
WO2018081567A1 (en) 2018-05-03
CA3041679A1 (en) 2018-05-03
EP3532063A1 (en) 2019-09-04
KR102543227B1 (ko) 2023-06-13
RU2019115258A3 (es) 2020-11-27
JP7543350B2 (ja) 2024-09-02
KR20190093563A (ko) 2019-08-09
CN110087653A (zh) 2019-08-02
US10231966B2 (en) 2019-03-19
EP3532063A4 (en) 2020-07-22
US20180117039A1 (en) 2018-05-03
JP2020500183A (ja) 2020-01-09
US20200261448A1 (en) 2020-08-20
BR112019008622A2 (pt) 2019-07-09
RU2763525C2 (ru) 2021-12-30
AU2017348354A1 (en) 2019-05-30
NZ753418A (en) 2024-05-31
US11364238B2 (en) 2022-06-21
JP2022169636A (ja) 2022-11-09
RU2019115258A (ru) 2020-11-27
MX2022000966A (es) 2022-02-14
KR20230093341A (ko) 2023-06-27

Similar Documents

Publication Publication Date Title
RS64283B1 (sr) Piridazinoni kao inhibitori parp7
HK1252378A1 (zh) 酪氨酸激酶抑制劑
MX2022013114A (es) Inhibidores de diana de rapamicina en celulas de mamifero de complejo 1 (mtorc1).
PH12018501151A1 (en) Tank-binding kinase inhibitor compounds
EP3399968A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
EP3648753A4 (en) SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE
EP3157425A4 (en) Systems and methods for planning, performing, and assessing spinal correction during surgery
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
TW201613916A (en) TANK-binding kinase inhibitor compounds
MX2021015826A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
HUE044240T2 (hu) Janus kináz (JAK) inhibitorok
PH12018500736A1 (en) Methods for treating multiple sclerosis using pyrimidine and pyridine compounds with btk inhibitory activity
EP3804707A4 (en) KINASE INHIBITORS
EP3145512A4 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
MX2022000966A (es) Politerapia para tratar hipertension pulmonar.
EP3927700A4 (en) KINAS INHIBITORS
WO2015179737A3 (en) Treatment of eosinophil or mast cell related disorders
EP3852762A4 (en) NEW EGFR QUINAZOLINE INHIBITORS
EP3844166C0 (en) SUBSTITUTED MACROCYCLES USEFUL AS KINASE INHIBITORS
ZA202108775B (en) New egfr inhibitors
EP3523285A4 (en) QUINOXALINE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
IL281599A (en) TYK2 kinase inhibitors
EP3986565C0 (en) NEW EGFR INHIBITORS
WO2016154329A3 (en) P38 map kinase inhibitors for treating friedreich's ataxia